Evidence map›Paper›PMID 37930128›Full record

ReviewHepatology communications2023

The Impact and Burden of Dietary Sugars on the Liver.

Helaina E Huneault, Ana Ramirez Tovar, Cristian Sanchez-Torres, Jean A Welsh, Miriam B Vos

Open access · goldAbstract readReview
In one paragraph

Review in Hepatology communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Helaina E HuneaultNutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, Georgia, USA.ORCID 0000-0003-3866-2387
Ana Ramirez TovarDivision of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-9038-6589
Cristian Sanchez-TorresDivision of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0314-5438
Jean A WelshNutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-1372-5524
Miriam B VosNutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-0817-7068
Emory University · US

Funding

Sibling Assessment in Prevention of Pediatric NAFLD in Hispanic ChildrenR01NR019083 · NINR · EMORY UNIVERSITY · PI WELSH, JEAN A. · 2021 to 2025
$3.3M
Biomarker Discovery for Nonalcoholic Fatty Liver Disease in ChildrenR01DK125701 · NIDDK · EMORY UNIVERSITY · PI VOS, MIRIAM B. · 2020 to 2022
$1.0M
NIDDK NIH HHS R01 DK125701NINR NIH HHS R01 NR019083
6 · The paper itself

Abstract

NAFLD, or metabolic dysfunction-associated steatotic liver disease, has increased in prevalence hand in hand with the rise in obesity and increased free sugars in the food supply. The causes of NAFLD are genetic in origin combined with environmental drivers of the disease phenotype. Dietary intake of added sugars has been shown to have a major role in the phenotypic onset and progression of the disease. Simple sugars are key drivers of steatosis, likely through fueling de novo lipogenesis, the conversion of excess carbohydrates into fatty acids, but also appear to upregulate lipogenic metabolism and trigger hyperinsulinemia, another driver. NAFLD carries a clinical burden as it is associated with obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease. Patient quality of life is also impacted, and there is an enormous economic burden due to healthcare use, which is likely to increase in the coming years. This review aims to discuss the role of dietary sugar in NAFLD pathogenesis, the health and economic burden, and the promising potential of sugar reduction to improve health outcomes for patients with this chronic liver disease.

Indexed as

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseDietary SugarsHumansObesityQuality of LifeSugarsDietary SugarsSugars

Identifiers

PMID37930128
PMCPMC10629746
OpenAlexW4388422856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.